clinical trial · NCT07079267
Olpasiran Expanded Access Program
Amgen·—·available
Olpasiran
brief summary
Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.
started
—
primary completion
—
completion
—
last updated
Jul 23, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol